Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D2TZ
|
|||
| Former ID |
DIB011044
|
|||
| Drug Name |
CMS-024-02
|
|||
| Synonyms |
Tyroserleutide; Tyroservatide; CMS-024; CMS-024); Tyroserleutide (iv, cancer), China Medical System; Tyroserleutide (iv, cancer), Shenzhen Kangzhe Pharmaceuticals; Tyroservatide (cancer), Shenzhen Kangzhe Pharmaceuticals/ China Medical System Holdings; Tyroserleutide (iv, cancer), Shenzhen Kangzhe Pharmaceuticals/ China Medical System; Tyrosyl-seryl-leucine (cancer), Tianjin Medical University/Shenzhen Kangzhe Pharmaceutical
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 3 | [1] | |
| Company |
Shenzhen Kangzhe Pharmaceutical Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H25N3O6
|
|||
| Canonical SMILES |
CC(C)C(C(=O)O)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)N
|
|||
| InChI |
1S/C17H25N3O6/c1-9(2)14(17(25)26)20-16(24)13(8-21)19-15(23)12(18)7-10-3-5-11(22)6-4-10/h3-6,9,12-14,21-22H,7-8,18H2,1-2H3,(H,19,23)(H,20,24)(H,25,26)/t12-,13-,14-/m0/s1
|
|||
| InChIKey |
TYFLVOUZHQUBGM-IHRRRGAJSA-N
|
|||
| CAS Number |
CAS 154039-16-4
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:165974
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histone deacetylase (HDAC) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01489566) Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients. U.S. National Institutes of Health. | |||
| REF 2 | US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.